EU Crunch Time For 15 New Drugs At Final CHMP Meeting Of 2021

Oral Explanation Meetings Possible For Four Marketing Applications

Drugs for COVID-19, Alzheimer’s disease and heavy menstrual bleeding due to uterine fibroids are among the latest products that are this week being considered for marketing approval by the European Medicine Agency’s human drugs evaluation committee, the CHMP.

Question marks background. High resolution 3d render
A number of companies are set to find out if their drugs will receive EU approval • Source: Alamy

The European Medicines Agency is this week set to decide whether to recommend pan-EU marketing approval for 15 new drugs, including Xevudy (sotrovimab),Vir Biotechnology/GlaxoSmithKline’s COVID-19 treatment, and linzagolix, from ObsEva, for managing heavy menstrual bleeding associated with uterine fibroids.

Xevudy, which is approved in a number of countries around the world, is intended for the treatment of adults and...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography